NVP is using HPLN as a base entity to obtain an advanced, nanoparticle based, ADC approach able to significantly reposition and enhance existing cancer therapies.
This is because HPLN provides a unique new nanoparticle encapsulated platform designed to harness and enable vastly superior targeting to tumor and other specific cell surface antigens. Also, unlike other targeted technologies, the ‘payload’ for HPLN can be more easily user selected, including proven cytotoxics, nucleic acid based entities or small molecules, or even any mixture thereof. HPLN technology is subject to broad patent control by NVP.
HPLN may serve as an important new, effective and safe drug delivery platform to initially treat both Ewing sarcoma and human adult leukemia as well as other CD99/CD19 based tumors, via our own in-house candidates and beyond via collaborative programs. Logically the technology is widely applicable to other malignancies and therapeutic or even diagnostic opportunities as further candidate options develop.
Why is HPLN unique?
We already have excellent chemotherapeutic compounds and rich knowledge in their everyday use, plus emerging tumor-specific biologicals. However, the key issues that our approach can clearly address include:
– Improving both efficacy and capability of existing agents in existing settings
– Improving applicability of existing drugs to ‘new cancers’
– Improving management of toxicity
– Improving scheduling practicalities with treatments
– Developing innovative or enhanced methods of delivering potential new entities or treatments either in oncology and other therapeutic areas